RT Journal Article
SR Electronic
T1 Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 1
OP 7
DO 10.1136/jcp-2023-209053
VO 77
IS 1
A1 Julve, Max
A1 Kennedy, Oliver
A1 Frampton, Adam Enver
A1 Bagwan, Izhar
A1 Lythgoe, Mark P
YR 2024
UL http://jcp.bmj.com/content/77/1/1.abstract
AB Cancer testis antigen gene 1B (CTAG1B) and its associated gene product; New York oesophageal squamous carcinoma 1 (NY-ESO-1), represent a unique and promising target for cancer immunotherapy. As a member of the cancer testis antigen family (CTA), the protein’s restricted expression pattern and ability to elicit spontaneous humoural and cellular immune responses has resulted in a plethora of novel modalities and approaches attempting to harness its immunotherapeutic anti-cancer potential. Here, we discuss the structure and function of CTAG1B/NY-ESO-1 in both health and disease, immunohistochemical detection, as well as the most promising advances in the development of associated anti-cancer therapies. From cancer vaccines to engineered cellular therapy approaches, a multitude of immunotherapies targeting CTA’s are coming to the forefront of oncology. Although the efficacy of such approaches have yet to provide convincing evidence of durable response, early phase clinical trial data has resulted in some exciting findings which will have significant potential to act as a platform for future practice changing technologies.